Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patientsErika Morsia, Naseema Gangat, Kristen McCullough et al.|American Journal of Hematology|2020Cited by 136
Phase1/‐2 study of Pomalidomide in myelofibrosisRuben A. Mesa, Ayalew Tefferi, Animesh Pardanani et al.|American Journal of Hematology|2009Cited by 87
Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMTZachariah DeFilipp, Bronwen E. Shaw, Philip L. McCarthy et al.|Biology of Blood and Marrow Transplantation|2016Cited by 64
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosisTania Jain, Jeanne Palmer, Katie L. Kunze et al.|Bone Marrow Transplantation|2018Cited by 46
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decadesJason P. Cooper, Brenda M. Sandmaier, Barry E. Storer et al.|Haematologica|2020Cited by 39